Nuveen Asset Management LLC purchased a new position in shares of Antares Pharma Inc (NASDAQ:ATRS) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 684,437 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,252,000. Nuveen Asset Management LLC owned about 0.42% of Antares Pharma as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Corrado Advisors LLC acquired a new position in shares of Antares Pharma during the 2nd quarter worth approximately $26,000. Bank of Montreal Can acquired a new position in shares of Antares Pharma during the 2nd quarter worth approximately $45,000. Aperio Group LLC acquired a new position in shares of Antares Pharma during the 2nd quarter worth approximately $47,000. Alpine Woods Capital Investors LLC increased its position in shares of Antares Pharma by 60.0% during the 2nd quarter. Alpine Woods Capital Investors LLC now owns 16,000 shares of the specialty pharmaceutical company’s stock worth $53,000 after purchasing an additional 6,000 shares during the last quarter. Finally, Prudential Financial Inc. increased its position in shares of Antares Pharma by 33.8% during the 2nd quarter. Prudential Financial Inc. now owns 18,530 shares of the specialty pharmaceutical company’s stock worth $61,000 after purchasing an additional 4,680 shares during the last quarter. 38.72% of the stock is currently owned by hedge funds and other institutional investors.

Shares of ATRS stock traded down $0.03 during trading on Wednesday, reaching $3.40. 8,566 shares of the company’s stock were exchanged, compared to its average volume of 666,402. The company has a quick ratio of 2.87, a current ratio of 3.46 and a debt-to-equity ratio of 1.01. The stock has a market capitalization of $560.93 million, a PE ratio of -85.13 and a beta of 0.82. Antares Pharma Inc has a twelve month low of $2.53 and a twelve month high of $3.96. The firm’s fifty day moving average price is $3.41 and its 200-day moving average price is $3.12.

Antares Pharma (NASDAQ:ATRS) last posted its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported ($0.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.03. The business had revenue of $28.43 million for the quarter, compared to analyst estimates of $21.66 million. Antares Pharma had a negative return on equity of 9.67% and a negative net margin of 4.03%. As a group, analysts anticipate that Antares Pharma Inc will post -0.08 EPS for the current fiscal year.

Separately, BidaskClub raised Antares Pharma from a “sell” rating to a “hold” rating in a research report on Saturday. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $5.04.

Antares Pharma Profile

Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

Featured Story: How to track put option volume

Institutional Ownership by Quarter for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.